Uncategorized
Biologics CDMO Market Size to Grow by USD 8.65 Billion, Availability of Cost-efficient Resources in Emerging Markets to Boost Growth – Technavio
Biologics CDMO Market Size to Grow by USD 8.65 Billion, Availability of Cost-efficient Resources in Emerging Markets to Boost Growth – Technavio
PR Newswire
NEW YORK, Nov. 17, 2022
NEW YORK, Nov. 17, 2022 /PRNewswire/ — The global biologics CDMO m…
Share this:
Biologics CDMO Market Size to Grow by USD 8.65 Billion, Availability of Cost-efficient Resources in Emerging Markets to Boost Growth - Technavio
PR Newswire
NEW YORK, Nov. 17, 2022
NEW YORK, Nov. 17, 2022 /PRNewswire/ -- The global biologics CDMO market size is set to grow by USD 8.65 billion from 2021 to 2026, according to Technavio. Moreover, the growth momentum of the market is expected to accelerate at a CAGR of 12.20% during the forecast period. Use our report analysis and insights for effective decision making. Download a FREE Sample Report
Key Market Drivers
The growth of the biologics CDMO market is attributed to factors such as the availability of cost-efficient resources in emerging markets. For instance, India is one of the most preferred countries for CDMOs. The country has more than 100 US FDA-approved manufacturing facilities, and the number of such facilities is growing. Companies such as LUPIN and Zydus Cadila have a strong presence in the country, which is increasing the share of the biologics CDMO market. India accounts for an estimated one-third of the revenue of the global biologics CDMO market.
Technavio has identified key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. Buy Now for detailed information about market dynamics
Biologics CDMO Market Type Outlook (Revenue, USD bn, 2021-2026)
- Mammalian - size and forecast 2021-2026
- Microbial - size and forecast 2021-2026
- Cell therapy services - size and forecast 2021-2026
Biologics CDMO Market Geography Outlook (Revenue, USD bn, 2021-2026)
- North America - size and forecast 2021-2026
- Europe - size and forecast 2021-2026
- Asia - size and forecast 2021-2026
- ROW - size and forecast 2021-2026
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View an Exclusive FREE Sample Report
Market Segmentation
The mammalian segment will be a significant contributor to market growth during the forecast period. Mammalian cell culture is the process of growing animal cells in vitro in a flask or dish. There are four types of mammalian cells, namely epithelial cells, fibroblasts, lymphocytes, and macrophages. Human proteins with high therapeutic potential, such as clotting factors, tissue plasminogen activators, and erythropoietin, are produced with mammalian cell culture. Recombinant proteins from mammalian cells are used in therapeutics for various diseases, ranging from diabetes to cancer. Mammalian cell culture technology is one of the well-established technologies for the production of vaccines in bulk. Hence, the use of this technology by biopharmaceutical companies for bulk vaccine production is supporting revenue generation in this market segment.
North America will account for 41% of the market's growth during the forecast period. This growth is attributed to factors such as rising patient awareness about the benefits of the use of biologics. Moreover, market growth in this region will be faster than the growth of the market in ROW. The US and Canada are the key countries for the biologics CDMO market in North America.
Major Biologics CDMO Companies
- AGC Biologics
- Binex Co. Ltd.
- Boehringer Ingelheim International GmbH
- Catalent Inc.
- Fujifilm Diosynth Biotechnologies USA Inc.
- JRS PHARMA GmbH and Co. KG
- Lonza Group Ltd.
- Rentschler Biopharma SE
- Samsung BioLogics Co. Ltd.
- WuXi Biologics (Cayman) Inc.
Get lifetime access to our Technavio Insights! Subscribe to our Basic Plan billed annually at USD 5000
Related Reports
Cancer Biologics Market by Product and Geography - Forecast and Analysis 2022-2026: The cancer biologics market share is expected to increase by USD 34.97 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.91%. This report extensively covers segmentation by product (monoclonal antibodies, vaccines, cell and gene therapy, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).
Plasma Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026: The plasma therapeutics market share is expected to increase by USD 8.98 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.1%. This report extensively covers segmentation by product (immunoglobulin, albumin, blood factors, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).
Biologics CDMO Market Scope | |
Report Coverage | Details |
Page number | 120 |
Base year | 2021 |
Forecast period | 2022-2026 |
Growth momentum & CAGR | Accelerate at a CAGR of 12.20% |
Market growth 2022-2026 | USD 8.65 billion |
Market structure | Fragmented |
YoY growth (%) | 11.07 |
Regional analysis | North America, Europe, Asia, and ROW |
Performing market contribution | North America at 41% |
Key consumer countries | US, Canada, China, Germany, and UK |
Competitive landscape | Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled | AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., Fujifilm Diosynth Biotechnologies USA Inc., JRS PHARMA GmbH and Co. KG, Lonza Group Ltd., Rentschler Biopharma SE, Samsung BioLogics Co. Ltd., and WuXi Biologics (Cayman) Inc. |
Market dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse Health Care Market Reports
Table of Contents
1. Executive Summary
1.1 Market Overview
2. Market Landscape
2.1 Market ecosystem
2.1.1 Parent market
Exhibit 01: Parent market
Exhibit 02: Market characteristics
2.2 Value chain analysis
Exhibit 03: Value chain analysis: Pharmaceuticals
2.2.1 Research and development (R&D) and drug discovery
2.2.2 Integration and product development
2.2.3 Manufacturing
2.2.4 Outbound logistics
2.2.5 Marketing and sales
2.2.6 Support services
3. Market Sizing
3.1 Market segment analysis
Exhibit 04: Market segments
3.2 Market size 2021
3.3 Market definition
Exhibit 05: Offerings of vendors included in the market definition
3.4 Market outlook: Forecast for 2021 - 2026
3.4.1 Estimating growth rates for emerging and high-growth markets
3.4.2 Estimating growth rates for mature markets
Exhibit 06: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibit 07: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 08: Five forces analysis 2021 & 2026
4.2 Bargaining power of buyers
Exhibit 09: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 10: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 11: Threat of new entrants
4.5 Threat of substitutes
Exhibit 12: Threat of substitutes
4.6 Threat of rivalry
Exhibit 13: Threat of rivalry
4.7 Market condition
Exhibit 14: Market condition - Five forces 2021
5. Market Segmentation by Type
5.1 Market segments
Exhibit 15: Type - Market share 2021-2026 (%)
5.2 Comparison by Type
Exhibit 16: Comparison by Type
5.3 Mammalian - Market size and forecast 2021-2026
Exhibit 17: Mammalian - Market size and forecast 2021-2026 ($ million)
Exhibit 18: Mammalian - Year-over-year growth 2021-2026 (%)
5.4 Microbial - Market size and forecast 2021-2026
Exhibit 19: Microbial - Market size and forecast 2021-2026 ($ million)
Exhibit 20: Microbial - Year-over-year growth 2021-2026 (%)
5.5 Cell therapy services - Market size and forecast 2021-2026
Exhibit 21: Cell therapy services - Market size and forecast 2021-2026 ($ million)
Exhibit 22: Cell therapy services - Year-over-year growth 2021-2026 (%)
5.6 Market opportunity by Type
Exhibit 23: Market opportunity by Type
6. Customer landscape
Exhibit 24: Customer landscape
7. Geographic Landscape
7.1 Geographic segmentation
Exhibit 25: Market share by geography 2021-2026 (%)
7.2 Geographic comparison
Exhibit 26: Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 27: North America - Market size and forecast 2021-2026 ($ million)
Exhibit 28: North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 29: Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 31: Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 32: Asia - Year-over-year growth 2021-2026 (%)
7.6 ROW - Market size and forecast 2021-2026
Exhibit 33: ROW - Market size and forecast 2021-2026 ($ million)
Exhibit 34: ROW - Year-over-year growth 2021-2026 (%)
7.7 Key leading countries
Exhibit 35: Key leading countries
7.8 Market opportunity by geography
Exhibit 36: Market opportunity by geography
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 Availability of cost-efficient resources in emerging markets
8.1.2 Strong research and development pipeline of biologics therapeutics
8.1.3 Growing need to focus on core competencies
8.2 Market challenges
8.2.1 Capacity utilization and constraints
8.2.2 Stringent policies related to entry of new biologics
8.2.3 Stereotypical nature of CDMOs
Exhibit 37: Impact of drivers and challenges
8.3 Market trends
8.3.1 Advent of big data
8.3.2 Strategic alliances and partnerships with pharma companies
8.3.3 Increasing approvals for new molecules and biosimilars?
9. Vendor Landscape
9.1 Vendor landscape
Exhibit 38: Vendor landscape
The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.
9.2 Landscape disruption
Exhibit 39: ?Landscape disruption?
Exhibit 40: Industry risks
10. Vendor Analysis
10.1 Vendors covered
Exhibit 41: Vendors covered
10.2 Market positioning of vendors
Exhibit 42: ?Market positioning of vendors?
10.3 AGC Biologics
Exhibit 43: AGC Biologics - Overview
Exhibit 44: AGC Biologics - Product and service
Exhibit 45: AGC Biologics - Key offerings
10.4 Binex Co. Ltd.
Exhibit 46: Binex Co. Ltd. - Overview
Exhibit 47: Binex Co. Ltd. - Product and service
Exhibit 48: Binex Co. Ltd. - Key offerings
10.5 Boehringer Ingelheim International GmbH
Exhibit 49: Boehringer Ingelheim International GmbH - Overview
Exhibit 50: Boehringer Ingelheim International GmbH - Business segments
Exhibit 51: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 52: Boehringer Ingelheim International GmbH - Segment focus
10.6 Catalent Inc.
Exhibit 53: Catalent Inc. - Overview
Exhibit 54: Catalent Inc. - Business segments
Exhibit 55: Catalent Inc. - Key offerings
Exhibit 56: Catalent Inc. - Segment focus
10.7 Fujifilm Diosynth Biotechnologies USA Inc.
Exhibit 57: Fujifilm Diosynth Biotechnologies USA Inc. - Overview
Exhibit 58: Fujifilm Diosynth Biotechnologies USA Inc. - Product and service
Exhibit 59: Fujifilm Diosynth Biotechnologies USA Inc. - Key offerings
10.8 JRS PHARMA GmbH and Co. KG
Exhibit 60: JRS PHARMA GmbH and Co. KG - Overview
Exhibit 61: JRS PHARMA GmbH and Co. KG - Product and service
Exhibit 62: JRS PHARMA GmbH and Co. KG - Key offerings
10.9 Lonza Group Ltd.
Exhibit 63: Lonza Group Ltd. - Overview
Exhibit 64: Lonza Group Ltd. - Business segments
Exhibit 65: Lonza Group Ltd. - Key offerings
Exhibit 66: Lonza Group Ltd. - Segment focus
10.10 Rentschler Biopharma SE
Exhibit 67: Rentschler Biopharma SE - Overview
Exhibit 68: Rentschler Biopharma SE - Product and service
Exhibit 69: Rentschler Biopharma SE - Key offerings
10.11 Samsung BioLogics Co. Ltd.
Exhibit 70: Samsung BioLogics Co. Ltd. - Overview
Exhibit 71: Samsung BioLogics Co. Ltd. - Business segments
Exhibit 72: Samsung BioLogics Co. Ltd. - Key offerings
10.12 WuXi Biologics (Cayman) Inc.
Exhibit 73: WuXi Biologics (Cayman) Inc. - Overview
Exhibit 74: WuXi Biologics (Cayman) Inc. - Business segments
Exhibit 75: WuXi Biologics (Cayman) Inc. - Key offerings
Exhibit 76: WuXi Biologics (Cayman) Inc. - Segment focus
11. Appendix
11.1 Scope of the report
11.1.1 Market definition
11.1.2 Objectives
11.1.3 Notes and Caveats
11.2 Currency conversion rates for US$
Exhibit 77: Currency conversion rates for US$
11.3 Research Methodology
Exhibit 78: Research Methodology
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: Information sources
11.4 List of abbreviations
Exhibit 81: List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Newsroom: https://newsroom.technavio.org/news/biologics-cdmomarket
View original content to download multimedia:https://www.prnewswire.com/news-releases/biologics-cdmo-market-size-to-grow-by-usd-8-65-billion-availability-of-cost-efficient-resources-in-emerging-markets-to-boost-growth---technavio-301680240.html
SOURCE Technavio
Uncategorized
February Employment Situation
By Paul Gomme and Peter Rupert The establishment data from the BLS showed a 275,000 increase in payroll employment for February, outpacing the 230,000…
Share this:
By Paul Gomme and Peter Rupert
The establishment data from the BLS showed a 275,000 increase in payroll employment for February, outpacing the 230,000 average over the previous 12 months. The payroll data for January and December were revised down by a total of 167,000. The private sector added 223,000 new jobs, the largest gain since May of last year.
Temporary help services employment continues a steep decline after a sharp post-pandemic rise.
Average hours of work increased from 34.2 to 34.3. The increase, along with the 223,000 private employment increase led to a hefty increase in total hours of 5.6% at an annualized rate, also the largest increase since May of last year.
The establishment report, once again, beat “expectations;” the WSJ survey of economists was 198,000. Other than the downward revisions, mentioned above, another bit of negative news was a smallish increase in wage growth, from $34.52 to $34.57.
The household survey shows that the labor force increased 150,000, a drop in employment of 184,000 and an increase in the number of unemployed persons of 334,000. The labor force participation rate held steady at 62.5, the employment to population ratio decreased from 60.2 to 60.1 and the unemployment rate increased from 3.66 to 3.86. Remember that the unemployment rate is the number of unemployed relative to the labor force (the number employed plus the number unemployed). Consequently, the unemployment rate can go up if the number of unemployed rises holding fixed the labor force, or if the labor force shrinks holding the number unemployed unchanged. An increase in the unemployment rate is not necessarily a bad thing: it may reflect a strong labor market drawing “marginally attached” individuals from outside the labor force. Indeed, there was a 96,000 decline in those workers.
Earlier in the week, the BLS announced JOLTS (Job Openings and Labor Turnover Survey) data for January. There isn’t much to report here as the job openings changed little at 8.9 million, the number of hires and total separations were little changed at 5.7 million and 5.3 million, respectively.
As has been the case for the last couple of years, the number of job openings remains higher than the number of unemployed persons.
Also earlier in the week the BLS announced that productivity increased 3.2% in the 4th quarter with output rising 3.5% and hours of work rising 0.3%.
The bottom line is that the labor market continues its surprisingly (to some) strong performance, once again proving stronger than many had expected. This strength makes it difficult to justify any interest rate cuts soon, particularly given the recent inflation spike.
unemployment pandemic unemploymentUncategorized
Mortgage rates fall as labor market normalizes
Jobless claims show an expanding economy. We will only be in a recession once jobless claims exceed 323,000 on a four-week moving average.
Share this:
Everyone was waiting to see if this week’s jobs report would send mortgage rates higher, which is what happened last month. Instead, the 10-year yield had a muted response after the headline number beat estimates, but we have negative job revisions from previous months. The Federal Reserve’s fear of wage growth spiraling out of control hasn’t materialized for over two years now and the unemployment rate ticked up to 3.9%. For now, we can say the labor market isn’t tight anymore, but it’s also not breaking.
The key labor data line in this expansion is the weekly jobless claims report. Jobless claims show an expanding economy that has not lost jobs yet. We will only be in a recession once jobless claims exceed 323,000 on a four-week moving average.
From the Fed: In the week ended March 2, initial claims for unemployment insurance benefits were flat, at 217,000. The four-week moving average declined slightly by 750, to 212,250
Below is an explanation of how we got here with the labor market, which all started during COVID-19.
1. I wrote the COVID-19 recovery model on April 7, 2020, and retired it on Dec. 9, 2020. By that time, the upfront recovery phase was done, and I needed to model out when we would get the jobs lost back.
2. Early in the labor market recovery, when we saw weaker job reports, I doubled and tripled down on my assertion that job openings would get to 10 million in this recovery. Job openings rose as high as to 12 million and are currently over 9 million. Even with the massive miss on a job report in May 2021, I didn’t waver.
Currently, the jobs openings, quit percentage and hires data are below pre-COVID-19 levels, which means the labor market isn’t as tight as it once was, and this is why the employment cost index has been slowing data to move along the quits percentage.
3. I wrote that we should get back all the jobs lost to COVID-19 by September of 2022. At the time this would be a speedy labor market recovery, and it happened on schedule, too
Total employment data
4. This is the key one for right now: If COVID-19 hadn’t happened, we would have between 157 million and 159 million jobs today, which would have been in line with the job growth rate in February 2020. Today, we are at 157,808,000. This is important because job growth should be cooling down now. We are more in line with where the labor market should be when averaging 140K-165K monthly. So for now, the fact that we aren’t trending between 140K-165K means we still have a bit more recovery kick left before we get down to those levels.
From BLS: Total nonfarm payroll employment rose by 275,000 in February, and the unemployment rate increased to 3.9 percent, the U.S. Bureau of Labor Statistics reported today. Job gains occurred in health care, in government, in food services and drinking places, in social assistance, and in transportation and warehousing.
Here are the jobs that were created and lost in the previous month:
In this jobs report, the unemployment rate for education levels looks like this:
- Less than a high school diploma: 6.1%
- High school graduate and no college: 4.2%
- Some college or associate degree: 3.1%
- Bachelor’s degree or higher: 2.2%
Today’s report has continued the trend of the labor data beating my expectations, only because I am looking for the jobs data to slow down to a level of 140K-165K, which hasn’t happened yet. I wouldn’t categorize the labor market as being tight anymore because of the quits ratio and the hires data in the job openings report. This also shows itself in the employment cost index as well. These are key data lines for the Fed and the reason we are going to see three rate cuts this year.
recession unemployment covid-19 fed federal reserve mortgage rates recession recovery unemploymentUncategorized
Inside The Most Ridiculous Jobs Report In History: Record 1.2 Million Immigrant Jobs Added In One Month
Inside The Most Ridiculous Jobs Report In History: Record 1.2 Million Immigrant Jobs Added In One Month
Last month we though that the January…
Share this:
Last month we though that the January jobs report was the "most ridiculous in recent history" but, boy, were we wrong because this morning the Biden department of goalseeked propaganda (aka BLS) published the February jobs report, and holy crap was that something else. Even Goebbels would blush.
What happened? Let's take a closer look.
On the surface, it was (almost) another blockbuster jobs report, certainly one which nobody expected, or rather just one bank out of 76 expected. Starting at the top, the BLS reported that in February the US unexpectedly added 275K jobs, with just one research analyst (from Dai-Ichi Research) expecting a higher number.
Some context: after last month's record 4-sigma beat, today's print was "only" 3 sigma higher than estimates. Needless to say, two multiple sigma beats in a row used to only happen in the USSR... and now in the US, apparently.
Before we go any further, a quick note on what last month we said was "the most ridiculous jobs report in recent history": it appears the BLS read our comments and decided to stop beclowing itself. It did that by slashing last month's ridiculous print by over a third, and revising what was originally reported as a massive 353K beat to just 229K, a 124K revision, which was the biggest one-month negative revision in two years!
Of course, that does not mean that this month's jobs print won't be revised lower: it will be, and not just that month but every other month until the November election because that's the only tool left in the Biden admin's box: pretend the economic and jobs are strong, then revise them sharply lower the next month, something we pointed out first last summer and which has not failed to disappoint once.
In the past month the Biden department of goalseeking stuff higher before revising it lower, has revised the following data sharply lower:
— zerohedge (@zerohedge) August 30, 2023
- Jobs
- JOLTS
- New Home sales
- Housing Starts and Permits
- Industrial Production
- PCE and core PCE
To be fair, not every aspect of the jobs report was stellar (after all, the BLS had to give it some vague credibility). Take the unemployment rate, after flatlining between 3.4% and 3.8% for two years - and thus denying expectations from Sahm's Rule that a recession may have already started - in February the unemployment rate unexpectedly jumped to 3.9%, the highest since February 2022 (with Black unemployment spiking by 0.3% to 5.6%, an indicator which the Biden admin will quickly slam as widespread economic racism or something).
And then there were average hourly earnings, which after surging 0.6% MoM in January (since revised to 0.5%) and spooking markets that wage growth is so hot, the Fed will have no choice but to delay cuts, in February the number tumbled to just 0.1%, the lowest in two years...
... for one simple reason: last month's average wage surge had nothing to do with actual wages, and everything to do with the BLS estimate of hours worked (which is the denominator in the average wage calculation) which last month tumbled to just 34.1 (we were led to believe) the lowest since the covid pandemic...
... but has since been revised higher while the February print rose even more, to 34.3, hence why the latest average wage data was once again a product not of wages going up, but of how long Americans worked in any weekly period, in this case higher from 34.1 to 34.3, an increase which has a major impact on the average calculation.
While the above data points were examples of some latent weakness in the latest report, perhaps meant to give it a sheen of veracity, it was everything else in the report that was a problem starting with the BLS's latest choice of seasonal adjustments (after last month's wholesale revision), which have gone from merely laughable to full clownshow, as the following comparison between the monthly change in BLS and ADP payrolls shows. The trend is clear: the Biden admin numbers are now clearly rising even as the impartial ADP (which directly logs employment numbers at the company level and is far more accurate), shows an accelerating slowdown.
But it's more than just the Biden admin hanging its "success" on seasonal adjustments: when one digs deeper inside the jobs report, all sorts of ugly things emerge... such as the growing unprecedented divergence between the Establishment (payrolls) survey and much more accurate Household (actual employment) survey. To wit, while in January the BLS claims 275K payrolls were added, the Household survey found that the number of actually employed workers dropped for the third straight month (and 4 in the past 5), this time by 184K (from 161.152K to 160.968K).
This means that while the Payrolls series hits new all time highs every month since December 2020 (when according to the BLS the US had its last month of payrolls losses), the level of Employment has not budged in the past year. Worse, as shown in the chart below, such a gaping divergence has opened between the two series in the past 4 years, that the number of Employed workers would need to soar by 9 million (!) to catch up to what Payrolls claims is the employment situation.
There's more: shifting from a quantitative to a qualitative assessment, reveals just how ugly the composition of "new jobs" has been. Consider this: the BLS reports that in February 2024, the US had 132.9 million full-time jobs and 27.9 million part-time jobs. Well, that's great... until you look back one year and find that in February 2023 the US had 133.2 million full-time jobs, or more than it does one year later! And yes, all the job growth since then has been in part-time jobs, which have increased by 921K since February 2023 (from 27.020 million to 27.941 million).
Here is a summary of the labor composition in the past year: all the new jobs have been part-time jobs!
But wait there's even more, because now that the primary season is over and we enter the heart of election season and political talking points will be thrown around left and right, especially in the context of the immigration crisis created intentionally by the Biden administration which is hoping to import millions of new Democratic voters (maybe the US can hold the presidential election in Honduras or Guatemala, after all it is their citizens that will be illegally casting the key votes in November), what we find is that in February, the number of native-born workers tumbled again, sliding by a massive 560K to just 129.807 million. Add to this the December data, and we get a near-record 2.4 million plunge in native-born workers in just the past 3 months (only the covid crash was worse)!
The offset? A record 1.2 million foreign-born (read immigrants, both legal and illegal but mostly illegal) workers added in February!
Said otherwise, not only has all job creation in the past 6 years has been exclusively for foreign-born workers...
... but there has been zero job-creation for native born workers since June 2018!
This is a huge issue - especially at a time of an illegal alien flood at the southwest border...
... and is about to become a huge political scandal, because once the inevitable recession finally hits, there will be millions of furious unemployed Americans demanding a more accurate explanation for what happened - i.e., the illegal immigration floodgates that were opened by the Biden admin.
Which is also why Biden's handlers will do everything in their power to insure there is no official recession before November... and why after the election is over, all economic hell will finally break loose. Until then, however, expect the jobs numbers to get even more ridiculous.
Wendy’s has a new deal for daylight savings time haters
Mortgage rates fall as labor market normalizes
Shipping company files surprise Chapter 7 bankruptcy, liquidation
Economic Earthquake Ahead? The Cracks Are Spreading Fast
February Employment Situation
Wendy’s teases new $3 offer for upcoming holiday
Inside The Most Ridiculous Jobs Report In Recent History: Record 1.2 Million Immigrant Jobs Added In One Month
Inside The Most Ridiculous Jobs Report In History: Record 1.2 Million Immigrant Jobs Added In One Month
-
Uncategorized2 weeks agoAll Of The Elements Are In Place For An Economic Crisis Of Staggering Proportions
-
Uncategorized1 month agoCathie Wood sells a major tech stock (again)
-
Uncategorized3 weeks agoCalifornia Counties Could Be Forced To Pay $300 Million To Cover COVID-Era Program
-
Uncategorized2 weeks agoApparel Retailer Express Moving Toward Bankruptcy
-
Uncategorized3 weeks agoIndustrial Production Decreased 0.1% in January
-
International2 days agoWalmart launches clever answer to Target’s new membership program
-
International2 days agoEyePoint poaches medical chief from Apellis; Sandoz CFO, longtime BioNTech exec to retire
-
Uncategorized3 weeks agoRFK Jr: The Wuhan Cover-Up & The Rise Of The Biowarfare-Industrial Complex